Study of EPI-001 in Patients With Androgenetic Alopecia
Phase I/IIa Study to Evaluate the Safety, Tolerability, and Efficacy of EPI-001 in Patients With Androgenetic Alopecia
This is a Phase I/IIa clinical study to evaluate the safety, tolerability, and preliminary efficacy of EPI-001 in patients with androgenetic alopecia.
In the Phase I portion, a traditional 3+3 dose-escalation design will be used to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EPI-001. Subjects will be followed for up to 24 weeks after administration.
In the Phase IIa portion, subjects will be randomized in a 2:1 ratio to receive either EPI-001 or placebo. Safety and efficacy will be evaluated through hair count assessment, hair diameter measurement, clinical photography, investigator assessment, expert panel assessment, and subject self-assessment during a follow-up period of up to 48 weeks.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Androgenetic alopecia (AGA) is one of the most common forms of hair loss in both men and women and is characterized by progressive hair follicle miniaturization associated with androgen sensitivity and genetic predisposition. Current treatment options for AGA are limited and may not provide sufficient therapeutic benefit for all patients.
EPI-001 is an autologous dermal papilla cell therapy intended for the treatment of androgenetic alopecia. This study is designed to evaluate the safety, tolerability, and efficacy of EPI-001 in subjects with androgenetic alopecia.
This study consists of two parts: a Phase I dose-escalation study and a Phase IIa dose-expansion study.
In the Phase I portion, subjects will receive a single administration of EPI-001 using a traditional 3+3 dose-escalation design to evaluate dose-limiting toxicity (DLT), determine the maximum tolerated dose (MTD), and establish the recommended Phase 2 dose (RP2D). Subjects will be followed for up to 24 weeks after administration.
In the Phase IIa portion, eligible subjects will be randomized in a 2:1 ratio to receive either EPI-001 at the RP2D or placebo. The study will evaluate efficacy through changes in total hair count and hair diameter, as well as investigator assessment, expert panel assessment based on clinical photographs, and subject self-assessment questionnaires. Subjects will undergo follow-up assessments for up to 48 weeks after administration.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Epibiotech Clinical Operations
- Numéro de téléphone: +82-70-4209-0556
- E-mail: info@epibiotech.com
Lieux d'étude
-
-
Seoul
-
Seoul, Seoul, Corée du Sud, 06973
- Recrutement
- Chung-Ang University Hospital
-
Contact:
- Chung-Ang University Hospital
- Numéro de téléphone: +82-1800-1114
-
Chercheur principal:
- Beom Joon Kim, MD, PhD.
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Male or female subjects aged 19 years or older
- Subjects diagnosed with androgenetic alopecia
- Subjects willing to maintain the same hairstyle, hair length, and hair color during the study period
- Subjects willing to refrain from prohibited hair-related products or procedures during the study period
- Subjects willing to undergo scalp tattooing and hair trimming for phototrichogram evaluation
- Subjects who voluntarily signed written informed consent
Exclusion Criteria:
- Subjects who used prohibited medications or therapies affecting hair growth within the protocol-defined period
- Subjects with scalp diseases or hair disorders other than androgenetic alopecia
- Subjects with autoimmune diseases affecting the scalp or hair
- Subjects with clinically significant cardiovascular, renal, endocrine, infectious, or systemic diseases
- Subjects positive for HBV, HCV, HIV, or syphilis screening tests
- Subjects with a history of hair transplantation, stem cell therapy, or gene therapy
- Subjects with hypersensitivity related to the investigational product or study procedures
- Pregnant or breastfeeding women
- Subjects who participated in another clinical study within the protocol-defined period
- Subjects judged inappropriate for study participation by the investigator
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: Placebo
|
Placebo control administered by subcutaneous injection to the scalp.
|
|
Expérimental: EPI-001
|
EPI-001 is an autologous dermal papilla cell-based investigational product administered by subcutaneous injection to the scalp for the treatment of androgenetic alopecia.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Incidence of Dose-Limiting Toxicities
Délai: Up to 4 weeks after administration
|
Up to 4 weeks after administration
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of Adverse Events and Local Adverse Events
Délai: Phase I: up to 24 weeks; Phase IIa: up to 48 weeks after administration
|
Phase I: up to 24 weeks; Phase IIa: up to 48 weeks after administration
|
|
|
Number of Participants With Clinically Significant Abnormal Vital Signs
Délai: Phase I: up to 24 weeks; Phase IIa: up to 48 weeks after administration
|
Clinically significant abnormal vital signs include abnormalities in systolic blood pressure, diastolic blood pressure, pulse rate, and body temperature.
|
Phase I: up to 24 weeks; Phase IIa: up to 48 weeks after administration
|
|
Number of Participants With Clinically Significant Laboratory Abnormalities
Délai: Phase I: up to 24 weeks; Phase IIa: up to 48 weeks after administration
|
Phase I: up to 24 weeks; Phase IIa: up to 48 weeks after administration
|
|
|
Investigator Assessment of Hair Growth Improvement Based on Clinical Photographs Using a 7-Point Scale
Délai: Phase I: Weeks 4, 12, and 24; Phase IIa: Weeks 12, 24, 36, and 48
|
Investigators assess hair growth improvement by comparing clinical photographs with baseline photographs using a 7-point scale ranging from -3 (greatly decreased) to +3 (greatly increased).
Higher scores indicate greater improvement.
|
Phase I: Weeks 4, 12, and 24; Phase IIa: Weeks 12, 24, 36, and 48
|
|
Subject Self-Assessment of Hair Growth Improvement Using a 7-Point Questionnaire Scale
Délai: Phase I: Weeks 4, 12, and 24; Phase IIa: Weeks 12, 24, 36, and 48
|
Participants assess overall hair growth improvement using a questionnaire evaluating whether hair became fuller, reduction in hair shedding, increase in hair thickness, improvement in hair gloss and elasticity, improvement in overall scalp appearance, and increase in hair growth rate.
Each item is scored on a 7-point scale ranging from -3 (greatly worsened) to +3 (greatly improved).
Higher scores indicate greater perceived improvement.
|
Phase I: Weeks 4, 12, and 24; Phase IIa: Weeks 12, 24, 36, and 48
|
|
Change From Baseline in Total Hair Count Assessed by Phototrichogram
Délai: Phase I: Week 24; Phase IIa: Weeks 12, 24, and 48
|
Total hair count is assessed as the number of hairs identified within the target assessment area using phototrichogram imaging.
Changes from baseline in total hair count within the target assessment area are evaluated.
|
Phase I: Week 24; Phase IIa: Weeks 12, 24, and 48
|
|
Change From Baseline in Mean Hair Diameter Assessed by Phototrichogram
Délai: Phase I: Week 24; Phase IIa: Weeks 12, 24, and 48
|
Mean hair diameter is assessed by measuring hair shaft thickness within the target assessment area using phototrichogram imaging.
Changes from baseline in mean hair diameter are evaluated.
|
Phase I: Week 24; Phase IIa: Weeks 12, 24, and 48
|
|
Expert Panel Assessment of Hair Growth Improvement Based on Clinical Photographs Using a 7-Point Scale
Délai: Phase IIa: Weeks 12, 24, 36, and 48
|
Expert panel members assess hair growth improvement by comparing clinical photographs with baseline photographs using a 7-point scale ranging from -3 (greatly decreased) to +3 (greatly increased).
Higher scores indicate greater improvement.
|
Phase IIa: Weeks 12, 24, 36, and 48
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- EPI-001-A101
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .